Tennis elbow

Physical Therapists Positioned to Serve as Primary Care Providers Throughout the U.S. Military

Retrieved on: 
Wednesday, January 31, 2024
Therapy, National security, Low back pain, Research, National Defense Authorization Act, Carpal tunnel syndrome, Joint base, Human, Element, Tennis elbow, Physical therapy, Value, DOD, Physical, Defense, Credentialing, Student, APTA, Nursing

ALEXANDRIA, Va., Jan. 31, 2024 /PRNewswire/ -- The American Physical Therapy Association announces that the U.S. Department of Defense will allow physical therapists to serve as primary care providers for neuromusculoskeletal conditions across all military settings. This designation is based on significant DOD analysis and further confirms the value and cost-effectiveness of early intervention physical therapy.

Key Points: 
  • ALEXANDRIA, Va., Jan. 31, 2024 /PRNewswire/ -- The American Physical Therapy Association announces that the U.S. Department of Defense will allow physical therapists to serve as primary care providers for neuromusculoskeletal conditions across all military settings.
  • "The Department of Defense's decision to elevate physical therapists as primary care providers for neuromusculoskeletal conditions is a testament to the effectiveness and efficiency of the physical therapist's role in our military health system," said Congressman Trent Kelly, R-Miss, who was responsible for ensuring that a request for further analysis of taking physical therapy primary care system-wide be included in the 2023 National Defense Authorization Act.
  • "It is entirely feasible for physical therapists to serve in a primary care [neuromusculoskeletal expert] role throughout the DOD," the report states.
  • The American Physical Therapy Association represents more than 100,000 physical therapists, physical therapist assistants, and physical therapy students nationwide.

United States MAXIGESIC IV (Paracetamol + Ibuprofen) Drug Insights and Market Forecasts, 2019-2022 and 2023-2032 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 14, 2023
Health, Pharmaceutical, Headache, Research, Pain, Tennis elbow, Clinical trial, Migraine, Patient, Phenylephrine, SWOT, Arthritis, Sore throat, Myalgia, Ibuprofen, Gamer, Paracetamol, Chronic pain, Hospital, Fever, Common, Chemical oxygen demand, Toothache, Medical device, Poultry farming, Dietary supplement, Pharmaceutical industry

The "United States MAXIGESIC IV Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States MAXIGESIC IV Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights about MAXIGESIC IV for acute pain in the United States.
  • A detailed picture of the MAXIGESIC IV for acute pain in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the MAXIGESIC IV for acute pain.
  • This report provides a detailed market assessment of MAXIGESIC IV for acute pain in the United States.

Ketamine Clinic in Japan for Inbound Medical Treatment: Nagoya Anesthesia Clinic

Retrieved on: 
Tuesday, November 14, 2023
Mental Health, Hospitals, Other Health, Other Travel, Health, Pharmaceutical, General Health, Destinations, Travel, Pain, Tennis elbow, OCD, PRP, Depression, History, Chronic pain, Patient, DSM-IV codes, Incidence, PTSD, Nursing, Ketamine

Nagoya Anesthesia Clinic ( https://nagoyamasui.com/2-2 ), located in Nagoya City, Aichi Prefecture, Japan, has initiated inbound medical treatment for treatment-resistant depression, other mental disorders, and intractable chronic pain, utilizing the groundbreaking drug Ketamine.

Key Points: 
  • Nagoya Anesthesia Clinic ( https://nagoyamasui.com/2-2 ), located in Nagoya City, Aichi Prefecture, Japan, has initiated inbound medical treatment for treatment-resistant depression, other mental disorders, and intractable chronic pain, utilizing the groundbreaking drug Ketamine.
  • Over the past 15 years, the clinic has provided ketamine therapy through more than 1300 ketamine infusions.
  • Drawing on their extensive experience of performing Ketamine infusions for various pain and mental disorders, Nagoya Anesthesia Clinic has established the Ketamine Clinic based on Ketamine's potent analgesic and antidepressant properties.
  • Nagoya Anesthesia Clinic "Ketamine Clinic" Information Page:

Nagoya Anesthesia Clinic Initiates Inbound Medical Treatment for Treatment-Resistant Depression and Intractable Chronic Pain Using Ketamine

Retrieved on: 
Tuesday, October 24, 2023
Other Travel, Pharmaceutical, General Health, Health, Destinations, Mental Health, Travel, Other Health, Post-traumatic stress disorder, Incidence, Chronic pain, OCD, PTSD, DSM-IV codes, Pain, Patient, Tennis elbow, Tic disorder, Dentistry, Pharmaceutical industry, Ketamine

Nagoya Anesthesia Clinic ( https://nagoyamasui.com/ ), located in Nagoya City, Aichi Prefecture, Japan, has commenced inbound medical treatment for treatment-resistant depression, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), and intractable chronic pain, utilizing the groundbreaking drug, Ketamine, starting in October 2023.

Key Points: 
  • Nagoya Anesthesia Clinic ( https://nagoyamasui.com/ ), located in Nagoya City, Aichi Prefecture, Japan, has commenced inbound medical treatment for treatment-resistant depression, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), and intractable chronic pain, utilizing the groundbreaking drug, Ketamine, starting in October 2023.
  • Nagoya Anesthesia Clinic, with its rich experience of performing over 1000 Ketamine infusions for various pain and mental disorders, has launched the Ketamine Clinic based on Ketamine's potent analgesic and antidepressant properties.
  • Nagoya Anesthesia Clinic is proud to be the first and only Ketamine Clinic in Japan and will begin accepting patients for inbound medical treatment of treatment-resistant depression, OCD, PTSD, and intractable chronic pain from October 2023.
  • Nagoya Anesthesia Clinic "Ketamine Clinic" Information Page:

Orthobiologics Show Great Promise for Less Invasive Treatment of Certain Musculoskeletal Conditions

Retrieved on: 
Tuesday, August 15, 2023
China Biologic Products, Tissue, Insurance, Osteoarthritis, Tendinopathy, American Academy of Orthopaedic Surgeons, ASC Technology Committee, Evidence-based medicine, Education, Hair, Tennis elbow, Pancreas, Cancer, American Academy, Research, Cell, Platelet-rich plasma, Inflammation, Lupus, FAQ, Elective surgery, Science, Regenerative medicine, Biopharmaceutical, MD, Patient, Physician, PRP, Radio, Liver, AAOS, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Rheumatoid arthritis, Pharmaceutical industry, Nursing

ROSEMONT, Ill., Aug. 15, 2023 /PRNewswire/ -- As orthopaedic medicine continues to advance through innovation, research and evidence-based medicine, the complexities and unknowns about newer treatments such as orthobiologics, may leave patients wondering if it is a viable treatment option for them. Orthobiologics, sometimes referred to as regenerative medicine, have shown great promise to treat conditions such as osteoarthritis; however, patients are seeking resources to understand if the treatment is right for them. To educate patients, the American Academy of Orthopaedic Surgeons (AAOS) developed an FAQ published on OrthoInfo.org, that outlines what orthobiologics are and the potential risks and benefits.

Key Points: 
  • Orthobiologics, sometimes referred to as regenerative medicine, have shown great promise to treat conditions such as osteoarthritis; however, patients are seeking resources to understand if the treatment is right for them.
  • To educate patients, the American Academy of Orthopaedic Surgeons (AAOS) developed an FAQ published on OrthoInfo.org , that outlines what orthobiologics are and the potential risks and benefits.
  • The regenerative therapies touted in radio ads or featured on highway billboards may not be grounded in science."
  • Dr. Dragoo recommends patients work with a reputable physician, ideally one who does clinical research in this area and tracks their patient-outcome results.

TendoNova Inks Partnership with AcCELLerated Biologics

Retrieved on: 
Wednesday, March 8, 2023
Tennis elbow, Injury, Pain, Atlanta Hawks, Tendinopathy, Physician, Tendon, Growth, Athlete, 1991–92 Atlanta Hawks season, Partnership, Debridement, Emory, Pharmaceutical industry, Ocelot

“The TendoNova Ocelot represents a great opportunity for improving the lives of over 30 million Americans affected by tendon pain,” said TendoNova CEO Mark A. Samuels.

Key Points: 
  • “The TendoNova Ocelot represents a great opportunity for improving the lives of over 30 million Americans affected by tendon pain,” said TendoNova CEO Mark A. Samuels.
  • “Our partnership with AcCELLerated Biologics will enable access to customers for their biologic products that are utilized adjacent to our Ocelot.”
    “For the past decade, AcCELLerated Biologics has been at the forefront of training and equipping physicians with new biologic tools useful in the treatment of a variety of injuries,” said AcCELLerated Biologics CEO Steve Whyte.
  • “Working with TendoNova allows us to expand our offering to help improve the surgical treatment that could be combined with biologics to produce positive outcomes.
  • TendoNova completed its manufacturing ramp-up in December 2022 and presently manufactures the Ocelot in Atlanta.

With Tennis Season Approaching, ZetrOZ Systems' Multi-Hour sam® Sport Treatment Helps Athletes with Elbow Pain and Recovery

Retrieved on: 
Tuesday, February 21, 2023
Forearm, Wrist, Arm, Pain, Athlete, Patient, Lactic acid, History of Sufism, Inflammation, Elbow, Government, FDA, Tennis elbow, Waste, Musculoskeletal injury, Medical imaging

TRUMBULL, Conn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- When tennis season begins, many professional and collegiate players will turn to pain medication for relief from lateral epicondylitis, colloquially referred to as tennis elbow.

Key Points: 
  • TRUMBULL, Conn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- When tennis season begins, many professional and collegiate players will turn to pain medication for relief from lateral epicondylitis, colloquially referred to as tennis elbow.
  • ZetrOZ Systems' sam® technology provides long-duration, low-intensity ultrasound therapy, clinically validated in more than 30 studies and in the successful treatment of more than 500,000 patients.
  • The pain can extend from the elbow into the forearm and wrist, and the severity can range from mild to debilitating.
  • The sam® Sport pain relief ultrasound device is the only FDA-cleared multi-hour ultrasound treatment that is approved for home use.

Tendonitis Treatment (Therapy, Surgery) Market Analysis Report 2022: A $280+ Billion Market by 2030 - Pricing Analysis, Product Pipeline Analysis, & Industry Analysis - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 15, 2022
Surgery, Health, Osteoporosis, Health, Incidence, Tennis elbow, Prevalence, Travel, Condition, Achilles tendinitis, Injury, Treatment, Sport, Diabetes, Osteoarthritis, USD, Growth, Investment, Tendinopathy, COVID-19, Chronic kidney disease-mineral and bone disorder, Arthritis, Dentistry, Pharmaceutical industry, Health insurance

In addition, the rising incidence of occupational injuries is anticipated to contribute to the development and growth of the industry over the forecast period.

Key Points: 
  • In addition, the rising incidence of occupational injuries is anticipated to contribute to the development and growth of the industry over the forecast period.
  • The growing global geriatric population is susceptible to bone disorders, diabetes, arthritis, osteoarthritis, osteoporosis, or tendonitis.
  • Industry participants that are constantly innovating advanced therapies and technologies in managing tendonitis are also contributing to the market growth.
  • Growing investments, industry collaborations, and increasing favorable government support are other key factors accelerating market growth.

Stā Active Rebrands as Fiix Body™

Retrieved on: 
Thursday, July 14, 2022
University of St. Thomas (Texas), Connective tissue, Association football, Solution, Therapy, Tennis elbow, Minnesota Twins, Love, MD, Time, Elbow, Minnesota Vikings, University, Pain, FDA, Tennis, Association, Online shopping, Life insurance, Sports equipment, United States Soccer Federation, Program

MINNEAPOLIS, July 14, 2022 /PRNewswire/ -- Sta Active, an innovative start-up that debuted in 2020 to deliver self-administered physical therapy treatments at home, is rebranding as Fiix Body.

Key Points: 
  • MINNEAPOLIS, July 14, 2022 /PRNewswire/ -- Sta Active, an innovative start-up that debuted in 2020 to deliver self-administered physical therapy treatments at home, is rebranding as Fiix Body.
  • "Four years ago, we set out to make it easier to treat tennis and golfer's elbow," says Tim Porth, president and co-founder of Fiix Body.
  • "Based on feedback, we've adjusted our name to more distinctly clarify our vision.Our mission is the same we Fiix Bodies so you can St Active."
  • The company also has launched a new website at fiixbody.com , which features user-friendly navigation, how-to videos and compelling testimonials that demonstrate The Fiix Elbow solution.

TendoNova wins FDA Clearance for Its New Microinvasive Ocelot Surgical Tool

Retrieved on: 
Wednesday, March 23, 2022
NFL, Tendinopathy, Podiatry, Korea Disease Control and Prevention Agency, Growth, Patient, Georgia Research Alliance, Ocelot, Sports medicine, Pain management, Pain, National Football League, Injury, Association, Technology, TENEX, Physician, Center, Athlete, NFL Player's Association Financial Registration Program, Emory University School of Medicine, Georgia Tech, Debridement, Tennis elbow, FDA, Atlanta Hawks, Elective surgery, Medical imaging

ATLANTA, March 23, 2022 /PRNewswire/ -- TendoNova, an emerging leader in microinvasive sports medicine procedures, is pleased to announce the FDA 510(k) clearance of its new Ocelot surgical tool, which uses an innovative technology for fragmentation or debridement of soft tissue.

Key Points: 
  • ATLANTA, March 23, 2022 /PRNewswire/ -- TendoNova, an emerging leader in microinvasive sports medicine procedures, is pleased to announce the FDA 510(k) clearance of its new Ocelot surgical tool, which uses an innovative technology for fragmentation or debridement of soft tissue.
  • TendoNova plans to manufacture the Ocelot in Georgia and is presently working to validate the Ocelot disposable component production.
  • Founded in 2017, TendoNova is a medical device company that is an emerging leader in microinvasive sports medicine procedures.
  • The company's initial product is the Ocelot TSD 1000, a patented, FDA cleared medical device for fragmentation or debridement of soft tissue.